Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression in animal models. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: This is a prospectively designed analysis of annual total kidney volume (TKV) and thrice annual estimated GFR (eGFR) measurements, from two 3-year studies of tolvaptan in 63 ADPKD subjects randomly matched 1:2 to historical controls by gender, hypertension, age, and baseline TKV or eGFR. Prespecified end points were group differences in log-TKV (primary) and eGFR (secondary) slopes for month 36 completers, using linear mixed model (LMM) analysis. Sensitivity analyses of primary and secondary end points included LMM using all subject data and mixed model repeated measures (MMRM) of change from baseline at each year. Pearson correlation tested the association between log-TKV and eGFR changes. RESULTS: Fifty-one subjects (81%) completed 3 years of tolvaptan therapy; all experienced adverse events (AEs), with AEs accounting for six of 12 withdrawals. Baseline TKV (controls 1422, tolvaptan 1635 ml) and eGFR (both 62 ml/min per 1.73 m(2)) were similar. Control TKV increased 5.8% versus 1.7%/yr for tolvaptan (P < 0.001, estimated ratio of geometric mean 0.96 [95% confidence interval 0.95 to 0.97]). Corresponding annualized eGFR declined: -2.1 versus -0.71 ml/min per 1.73 m(2)/yr (P = 0.01, LMM group difference 1.1 ml/min per 1.73 m(2)/yr [95% confidence interval 0.24 to 1.9]). Sensitivity analyses including withdrawn subjects were similar, whereas MMRM analyses were significant at each year for TKV and nonsignificant for eGFR. Increasing TKV correlated with decreasing eGFR (r = -0.21, P < 0.01). CONCLUSION: ADPKD cyst growth progresses more slowly with tolvaptan than in historical controls, but AEs are common.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328 · cited 2×
“Control data were gathered from participants in the CRISP and MDRD studies (7,10,13).”
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Self-citation
Cited by
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Self-citationIrazabal, M. V., Rangel, L. J., Bergstralh, E. J., Osborn, S. L., Harmon, A. J., Sundsbak, J. L., Bae, K. T., Chapman, A. B., Grantham, J. J., Mrug, M., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013101138 · Cited by 625
Self-citationFunctional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity
Hopp, K., Ward, C. J., Hommerding, C. J., Nasr, S. H., Tuan, H.-F., Gainullin, V. G., Rossetti, S., Torres, V. E., & Harris, P. C. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64313 · Cited by 442
“The observation that the majority of adult cysts are of CD origin correlates with the AVPR2 antagonists showing some benefit in ADPKD (31, 32, 78).”
Self-citationStrategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease
Torres, V. E., & Harris, P. C. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040398 · Cited by 289
Self-citationA Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Chebib, F. T., Perrone, R. D., Chapman, A. B., Dahl, N. K., Harris, P. C., Mrug, M., Mustafa, R. A., Rastogi, A., Watnick, T., Yu, A. S. L., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018060590 · Cited by 257
Self-citation
Metadata
- Authors
- Higashihara, E., Torres, V. E., Chapman, A. B., Grantham, J. J., Bae, K., Watnick, T. J., Horie, S., Nutahara, K., Ouyang, J., Krasa, H. B., & Czerwiec, F. S.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2011-10
- Volume
- 6
- Issue
- 10
- Pages
- 2499-2507
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2096450143
- Cited by
- 149
- References
- 2
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience. https://app.cochat.ai/papers/10.2215/cjn.03530411
- The paper
- Higashihara, E., Torres, V. E., Chapman, A. B., Grantham, J. J., Bae, K., Watnick, T. J., Horie, S., Nutahara, K., Ouyang, J., Krasa, H. B., & Czerwiec, F. S. (2011). Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.03530411
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.